New combo therapy aims to improve outcomes for older CLL patients
NCT ID NCT07321652
First seen Jan 09, 2026 · Last updated May 14, 2026 · Updated 11 times
Summary
This study compares a fixed-duration combination of two drugs (zanubrutinib and sonrotoclax) against continuous zanubrutinib alone in older adults with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if the combination improves how long patients live without their cancer getting worse. About 466 participants will be enrolled, and the study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.